Ookuma Kazu 大隈和

… Alternative Names

OKUMA Kazu 大隈和

Less

Researcher Number	80315085
Other IDs
Affiliation (Current)	2025: 関西医科大学, 医学部, 教授
Affiliation (based on the past Project Information) *help	2024: 関西医科大学, 医学部, 教授 2021 – 2022: 関西医科大学, 医学部, 教授 2020: 国立感染症研究所, 血液・安全性研究部, 室長 2015 – 2017: 国立感染症研究所, 血液・安全性研究部, 室長 2008 – 2013: National Institute of Infectious Diseases, 血液・安全性研究部, 室長
Review Section/Research Field	Principal Investigator Experimental pathology / Basic Section 49030:Experimental pathology-related / Basic Section 42040:Laboratory animal science-related Except Principal Investigator Pathological medical chemistry
Keywords	Principal Investigator ヒト化マウス / VSV / HTLV-1 / 感染実験動物モデル / 新規治療薬 / エイズ / 宿主細胞内侵入機構 / 治療薬 / 薬剤耐性変異株 / SARS-CoV-2 … More / サル感染モデル / 発症予防・治療薬 / ニホンザル / 治療法 / ハイリスクキャリア / STLV-1 / 緑膿菌エキソトキシン / CCL17 / CCR4 / プロウイルス量 / ATL発症予防 / 緑膿菌エクソトキシン / CRTAM / TSLC1 / 標的化 / 感染細胞 / 疾患発症予防 / ウイルス療法 / HTLV-1エンベロープタンパク質 / HTLV-1感染受容体 / 組換え水疱性口内炎ウイルス / HTLV-1感染制御 / ヒト化マウス感染モデル / 組換えウイルス治療薬 / 組換えタンパク質治療薬 / 治療法開発 / HTLV-1感染細胞 / HTLV-1感染 / 感染モデル / ヒト免疫不全ウイルス１型 / ヒト免疫不全ウイルス1型 … More Except Principal Investigator HCV感染 / B細胞リンパ腫 / 分子腫瘍学 / HCV 感染 / B 細胞リンパ腫 / A20 Less

Development of novel therapeutic agents against SARS-CoV-2 drug-resistant mutants by applying the host cellular entry mechanismPrincipal Investigator
- Principal Investigator
  
  大隈和
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 49030:Experimental pathology-related
- Research Institution
  Kansai Medical University
Development of preventive/therapeutic drugs for HTLV-1 high-risk carriers and evaluation using a monkey infection modelPrincipal Investigator
- Principal Investigator
  
  OKUMA Kazu
- Project Period (FY)
  2020 – 2022
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 42040:Laboratory animal science-related
- Research Institution
  Kansai Medical University
  National Institute of Infectious Diseases
Development of anti-HTLV-1 therapies towards active interventions for high-risk carriersPrincipal Investigator
- Principal Investigator
  
  OKUMA Kazu
- Project Period (FY)
  2015 – 2017
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Experimental pathology
- Research Institution
  National Institute of Infectious Diseases
Development of a novel therapeutic for AIDS using humanized mouse model and improvement of HAARTPrincipal Investigator
- Principal Investigator
  
  OKUMA Kazu
- Project Period (FY)
  2011 – 2013
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Experimental pathology
- Research Institution
  National Institute of Infectious Diseases
Research on the mechanism of tumorigenesis by A20 dysfunction in HCV-infected B cells
- Principal Investigator
  
  KUSUNOKI Hideki
- Project Period (FY)
  2011 – 2012
- Research Category
  
  Grant-in-Aid for Challenging Exploratory Research
- Research Field
  
  Pathological medical chemistry
- Research Institution
  National Institute of Infectious Diseases
Development of a novel therapeutic for AIDS rapidly disseminating in Okinawa and evaluation of it using humanized mouse modelPrincipal Investigator
- Principal Investigator
  
  OKUMA Kazu
- Project Period (FY)
  2008 – 2010
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Experimental pathology
- Research Institution
  National Institute of Infectious Diseases

All 2022 2018 2017 2016 2015 2012 2011 2010 2009 2008

All Journal Article Presentation Patent

[Journal Article] Cytolytic Recombinant Vesicular Stomatitis Viruses Expressing STLV-1 Receptor Specifically Eliminate STLV-1 Env-Expressing Cells in an HTLV-1 Surrogate Model In Vitro2022
- Author(s)
  Seki Y, Kitamura T, Tezuka K, Murata M, Akari H, Hamaguchi I, Okuma K.
- Journal Title
  
  Viruses
  
  Volume: 14 Issue: 4 Pages: 740-740
- DOI
  10.3390/v14040740
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K06465, KAKENHI-PROJECT-21K06007, KAKENHI-PROJECT-22K08594
[Journal Article] Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor.2018
- Author(s)
  Tezuka K, Okuma K, Kuramitsu M, Matsuoka S, Tanaka R, Tanaka Y, Hamaguchi I.
- Journal Title
  
  Journal of Virology
  
  Volume: 92(4) Issue: 4
- DOI
  10.1128/jvi.01885-17
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-15K08439, KAKENHI-PROJECT-15K09462, KAKENHI-PROJECT-16K19590
[Journal Article] Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo.2015
- Author(s)
  Okuma K, Hiyoshi M, Tateyama S, Takizawa K, Saito M, Kuramitsu M, Araki K, Morishita K, Okada S, Yamamoto N, Biragyn A, Yamaguchi K, Hamaguchi I.
- Journal Title
  
  Retrovirology
  
  Volume: 12 Issue: 1 Pages: 1-14
- DOI
  10.1186/s12977-015-0199-8
- Peer Reviewed / Acknowledgement Compliant / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K08439, KAKENHI-PROJECT-15K09462, KAKENHI-PROJECT-15K15087, KAKENHI-PROJECT-25293081
[Journal Article] A-recombinant vesicular stomatitis virus encoding HIV-1 receptors and human OX40 ligand efficiently eliminates HIV-1-infected CM-positive Tcells expressing OX402011
- Author(s)
  K.Okuma, C.Tsuruno.
- Journal Title
  
  Human Immunology
  
  Volume: 72(4) Pages: 295-304
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20590403
[Journal Article] A recombinant vesicular stomatitis virus encoding HIV-1 receptors and human OX40 ligand efficiently eliminates HIV-1-infected CD4-positive T cells expressing OX402011
- Author(s)
  Okuma K, Tsuruno C, Takahashi Y, Tanaka R, Tanaka Y, Takahama Y, Hamaguchi Y, Hamaguchi I, Yamaguchi K
- Journal Title
  
  Human Immunology 72(4)
  
  Pages: 295-304
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20590403
[Journal Article] The novel CXCR4 antagonist, KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection : comparative studies with AMD31002009
- Author(s)
  Murakami T, Kumakura S, Yamazaki T, Tanaka R, Hamatake M, Okuma K, Huang W, Toma J, Komano J, Yanaka M, Tanaka Y, Yamamoto N
- Journal Title
  
  Antimicrobial Agents and Chemotherapy 53(7)
  
  Pages: 2940-2948
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20590403
[Patent] 組換え水疱性口内炎ウイルスを用いたワクチン・治療薬開発に向けたモニタリングのためのウイルスベクター定量法2017
- Inventor(s)
  大隈　和、手塚健太、浜口　功
- Industrial Property Rights Holder
  大隈　和、手塚健太、浜口　功
- Industrial Property Rights Type
  特許
- Industrial Property Number
  2017-131361
- Filing Date
  2017
- Data Source
  KAKENHI-PROJECT-15K08439
[Presentation] Establishment of a Novel HTLV-1-specific CCR4-targeting Therapy Using a CCL17-bound Oligonucleotide Delivery System2017
- Author(s)
  Kazu Okuma, Kenta Tezuka, Madoka Kuramitsu, Arya Biragyn, Isao Hamaguchi
- Organizer
  18th International Conference on Human Retrovirology
- Place of Presentation
  Tokyo
- Year and Date
  2017-03-07
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K08439
[Presentation] Oncolytic recombinant vesicular stomatitis viruses encoding HTLV-1 receptor control HTLV-1 infection in vitro and in vivo.2017
- Author(s)
  Kazu Okuma, Kenta Tezuka, Madoka Kuramitsu, Yuetsu Tanaka, Reiko Tanaka, Isao Hamaguchi.
- Organizer
  第65回日本ウイルス学会学術集会
- Data Source
  KAKENHI-PROJECT-15K08439
[Presentation] CCL17結合オリゴヌクレオチド導入システムを用いたHTLV-1特異的新規CCR4分子標的療法の開発2016
- Author(s)
  大隈和、手塚健太、倉光球、浜口功
- Organizer
  第3回日本HTLV-1学会学術集会
- Place of Presentation
  鹿児島
- Year and Date
  2016-08-26
- Data Source
  KAKENHI-PROJECT-15K08439
[Presentation] TARC結合組換えトキシンによるCCR4・Furin依存的なHTLV-1感染制御2015
- Author(s)
  大隈和、日吉真照、滝澤和也、齋藤益満、倉光球、浜口功
- Organizer
  第2回日本HTLV-1学会学術集会
- Place of Presentation
  東京
- Year and Date
  2015-08-21
- Data Source
  KAKENHI-PROJECT-15K08439
[Presentation] Recombinant vesicular stomatitis viruses targeting HIV-1-infected cells control HIV-1 infection in a humanized mouse model2012
- Author(s)
  Okuma K
- Organizer
  American Society for Virology, 31st Annual Meeting
- Place of Presentation
  Madison, WI, U.S.A.
- Data Source
  KAKENHI-PROJECT-23590481
[Presentation] Recombinant vesicular stomatitis viruses targeting HIV-1-infected cells control HIV-1 infection in a humanized mouse model2012
- Author(s)
  Okuma K, Watanabe S, Tanaka Y, Yamamoto N, Rose JK, Hamaguchi I
- Organizer
  American Society for Virology, 31st Annual Meeting
- Place of Presentation
  Madison, WI, U.S.A
- Data Source
  KAKENHI-PROJECT-23590481
[Presentation] Development of a recombinant vesicular stomatitis virus that targets CCR5-tropic HIV-1-infected cells and inhibits HIV-1 infection2011
- Author(s)
  Okuma K
- Organizer
  American Society for Virology, 30th Annual Meeting
- Place of Presentation
  Minneapolis, MN, U.S.A.
- Data Source
  KAKENHI-PROJECT-23590481
[Presentation] ヒト化NOGマウスを用いたR5 HIV-1標的組換えVSVの薬効性評価2011
- Author(s)
  大隈和、深川耕次、高馬卓也、渡辺哲、田中勇悦、山本直樹、浜口功
- Organizer
  第25回日本エイズ学会学術集会
- Place of Presentation
  東京
- Data Source
  KAKENHI-PROJECT-23590481
[Presentation] Development of a recombinant vesicular stomatitis virus that targets CCR5-tropic HIV-1-infected cells and inhibits HIV-1 infection2011
- Author(s)
  Okuma K, Tanaka R, Hamaguchi I, Rose JK, Tanaka Y
- Organizer
  American Society for Virology, 30th Annual Meeting
- Place of Presentation
  Minneapolis, MN, U.S.A
- Data Source
  KAKENHI-PROJECT-23590481
[Presentation] ヒト化NOGマウスを用いたX4 HIV-1標的組換えVSVの治療効果の検討2010
- Author(s)
  大隈和
- Organizer
  第24回日本エイズ学会学術集会
- Place of Presentation
  東京(グランドプリンス高輪)
- Data Source
  KAKENHI-PROJECT-20590403
[Presentation] R5 HIV-1感染を制御する組換えVSVの開発とOX40L発現による効果増強2010
- Author(s)
  大隈和
- Organizer
  第58回日本ウイルス学会学術集会
- Place of Presentation
  徳島(あわぎんホール)
- Data Source
  KAKENHI-PROJECT-20590403
[Presentation] A recombinant vesicular stomatitis virus encoding HIV-1 receptors and OX40 ligand as a novel potential anti-HIV-1 therapeutic agent2010
- Author(s)
  大隈和
- Organizer
  XVIII International AIDS Conference
- Place of Presentation
  Vienna, Austria
- Year and Date
  2010-07-19
- Data Source
  KAKENHI-PROJECT-20590403
[Presentation] ヒト化NOGマウスを用いたX4 HIV-1標的組換えVSVの治療効果の検討2010
- Author(s)
  大隈和
- Organizer
  第24回日本エイズ学会学術集会
- Place of Presentation
  東京
- Year and Date
  2010-11-25
- Data Source
  KAKENHI-PROJECT-20590403
[Presentation] CD4、CXCR4を併せ持つ新規HIV攻撃用VSVの作製:OX40リガンド共発現の効果2009
- Author(s)
  大隈和
- Organizer
  第57回日本ウイルス学会学術集会
- Place of Presentation
  東京
- Year and Date
  2009-10-26
- Data Source
  KAKENHI-PROJECT-20590403
[Presentation] 新規バイオ治療薬候補のヒト化マウス感染モデルを用いた評価:CCR5指向性HIV-1感染細胞を選択的に破壊する組換えウイルスVSV2009
- Author(s)
  大隈和
- Organizer
  第23回日本エイズ学会学術集会
- Place of Presentation
  名古屋
- Year and Date
  2009-11-28
- Data Source
  KAKENHI-PROJECT-20590403
[Presentation] R5 HIV-1感染細胞を標的とし感染を制御する組換えウイルスVSV2008
- Author(s)
  大隈和
- Organizer
  第22回日本エイズ学会学術集会
- Place of Presentation
  大阪
- Year and Date
  2008-11-27
- Data Source
  KAKENHI-PROJECT-20590403
[Presentation] R5 HIV-1感染細胞を標的とし感染を制御する組換えウイルスVSV2008
- Author(s)
  大隈和
- Organizer
  第22回日本エイズ学会学術集会・総会
- Place of Presentation
  大阪市
- Year and Date
  2008-11-27
- Data Source
  KAKENHI-PROJECT-20590403
[Presentation] A novel potential anti-HIV-1 therapeutic based on a vesicular stomatitis virus expressing HIV-1 receptors and OX40 ligand2008
- Author(s)
  Kazu Okuma
- Organizer
  XVII International AIDS Conference
- Place of Presentation
  Mexico City, Mexico
- Year and Date
  2008-08-05
- Data Source
  KAKENHI-PROJECT-20590403

1. TANAKA Yuetsu (30163588)

# of Collaborated Projects: 2 results

# of Collaborated Products: 5 results
2. FUJITA Jiro (80209056)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
3. KUSUNOKI Hideki (90334060)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
4. MIZUOCHI Toshiaki (30135701)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results

Ookuma Kazu 大隈 和

OKUMA Kazu 大隈 和

Research Projects

Research Products

Co-Researchers

Development of novel therapeutic agents against SARS-CoV-2 drug-resistant mutants by applying the host cellular entry mechanismPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of preventive/therapeutic drugs for HTLV-1 high-risk carriers and evaluation using a monkey infection modelPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of anti-HTLV-1 therapies towards active interventions for high-risk carriersPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of a novel therapeutic for AIDS using humanized mouse model and improvement of HAARTPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Research on the mechanism of tumorigenesis by A20 dysfunction in HCV-infected B cells

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of a novel therapeutic for AIDS rapidly disseminating in Okinawa and evaluation of it using humanized mouse modelPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Cytolytic Recombinant Vesicular Stomatitis Viruses Expressing STLV-1 Receptor Specifically Eliminate STLV-1 Env-Expressing Cells in an HTLV-1 Surrogate Model In Vitro2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor.2018

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo.2015

Author(s)

Journal Title

DOI

Data Source

[Journal Article] A-recombinant vesicular stomatitis virus encoding HIV-1 receptors and human OX40 ligand efficiently eliminates HIV-1-infected CM-positive Tcells expressing OX402011

Author(s)

Journal Title

Data Source

[Journal Article] A recombinant vesicular stomatitis virus encoding HIV-1 receptors and human OX40 ligand efficiently eliminates HIV-1-infected CD4-positive T cells expressing OX402011

Author(s)

Journal Title

Data Source

[Journal Article] The novel CXCR4 antagonist, KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection : comparative studies with AMD31002009

Author(s)

Journal Title

Data Source

[Patent] 組換え水疱性口内炎ウイルスを用いたワクチン・治療薬開発に向けたモニタリングのためのウイルスベクター定量法2017

Inventor(s)

Industrial Property Rights Holder

Industrial Property Rights Type

Industrial Property Number

Filing Date

Data Source

[Presentation] Establishment of a Novel HTLV-1-specific CCR4-targeting Therapy Using a CCL17-bound Oligonucleotide Delivery System2017

Author(s)

Organizer

Place of Presentation

Year and Date

Ookuma Kazu 大隈和

OKUMA Kazu 大隈和